Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Slides:

Advertisements

Similar presentations

Roberts AW et al. Proc ASH 2014;Abstract 325.

Advertisements

Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-

A new possible conditionning regimen before Autologous Stem Cell Transplantation for refractory high-grade lymphoma Z-BeEAM (Ibritumomab tiuxetan, Bendamustine,

Reeder CB et al. ASCO 2009; Abstract (Poster)

Oki Y et al. Proc ASH 2013;Abstract 252.

Dose-escalation patient response.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

Ferrajoli A et al. Proc ASH 2010;Abstract 1395.

A, baseline and 4-week PET scan from patient 2 (MET c

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Clinical responses in patients.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Evaluation of clinical responses after infusion of CART19 cells

Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

Pseudoresponse. Pseudoresponse. A 47-year-old man with GBM. A reduction of the enhancing portion of the lesion is observed 1 day after initiation of cediranib.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

coTCRcys-transduced T cells control tumor growth in vivo.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.

Immunologic and pharmacokinetic studies.

Duration of treatment and intervals of radiographic and ctDNA response

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

Impairment of liver function upon treatment with 4D5MOCB-ETA.

Evaluation of clinical responses after infusion of CART19 cells

Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.

6-TG dose and time relationships for DSB formation using PFGE, demonstrating that the formation of DSBs in both MMR+ M4 and MMR− V2 cells is dose dependent.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Effect of CDV on human SF7796 xenografts in vivo.

Macroscopic observations of the mogamulizumab-induced skin-related AEs

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Change in FES uptake in the tumor during fulvestrant treatment.

Frequent coamplification of RTKs in MET-amplified EGC

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

Representative patient responses to ulixertinib.

A, Selected 4 quantitative imaging features significantly associated with 3 imaging subtypes, including tumor volume, tumor sphericity, tumor homogeneity.

A, transversal and coronal microPET images of 89Zr-ranibizumab at 24 hours pi of the tracer. A, transversal and coronal microPET images of 89Zr-ranibizumab.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Comparative effect of anti-TIM3 against experimental tumors.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

PDL192 and inhibit the growth of xenograft tumors.

Schedule-dependent impact of costimulated activated T-cell transfer on T-cell reconstitution after tandem stem cell transplant. Schedule-dependent impact.

Representative biodistribution pattern of 111In-CMD-193.

Serial CT scan images from patient with a partial response.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic imaging for patient A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A, abdominal CT imaging of 77-year-old patient with rituximab and chemotherapy-refractory CLL treated with DT2219 at dose level 40 μg/kg every other day × 4 doses before and at day 28 after therapy is shown. The 40% reduction in the abdominal tumor mass was observed after a single course of therapy. B, CT images of a 53-year-old female with CD22+CD19+ relapsed chemotherapy refractory marginal zone lymphoma. The patient was treated at dose level 60 μg/kg/day QOD×4 and experienced a DLT of capillary leak syndrome and neutropenia. After regulatory approval, the patient received a second treatment course 8 weeks later at a reduced dose of 40 μg/kg/day QOD×4, which resulted in complete resolution of the tumor mass. CT images were taken before therapy and after the second course of DT2219. Arrows indicate a tumor mass. Veronika Bachanova et al. Clin Cancer Res 2015;21:1267-1272 ©2015 by American Association for Cancer Research